Rchr
J-GLOBAL ID:201901001476108367   Update date: Mar. 08, 2024

Kato Katsuhiro

カトウ カツヒロ | Kato Katsuhiro
Research field  (1): Cardiology
Research theme for competitive and other funds  (3):
  • 2022 - 2026 免疫チェックポイント阻害薬による自己抗体関連有害事象の検証を目的とした研究
  • 2022 - 2025 肺細動脈内皮細胞で特徴的変化を示す分子に着目した肺高血圧症への新規治療戦略の開発
  • 2020 - 2022 肺細動脈内皮細胞に着目した肺高血圧症に対する新規治療戦略の開発を目指した病態解明
Papers (47):
  • Haruko Watanabe-Takano, Katsuhiro Kato, Eri Oguri-Nakamura, Tomohiro Ishii, Koji Kobayashi, Takahisa Murata, Koichiro Tsujikawa, Takaki Miyata, Yoshiaki Kubota, Yasuyuki Hanada, et al. Endothelial cells regulate alveolar morphogenesis by constructing basement membranes acting as a scaffold for myofibroblasts. Nature communications. 2024. 15. 1. 1622-1622
  • Ryota Ando, Yukihiro Shiraki, Yuki Miyai, Hiroki Shimizu, Kazuhiro Furuhashi, Shun Minatoguchi, Katsuhiro Kato, Akira Kato, Tadashi Iida, Yasuyuki Mizutani, et al. Meflin is a marker of pancreatic stellate cells involved in fibrosis and epithelial regeneration in the pancreas. The Journal of pathology. 2023
  • Yuta Ozaki, Koji Ohashi, Naoya Otaka, Hiroshi Kawanishi, Tomonobu Takikawa, Lixin Fang, Kunihiko Takahara, Minako Tatsumi, Sohta Ishihama, Mikito Takefuji, et al. Myonectin protects against skeletal muscle dysfunction in male mice through activation of AMPK/PGC1α pathway. Nature communications. 2023. 14. 1. 4675-4675
  • Fumiya Ito, Katsuhiro Kato, Izumi Yanatori, Yuki Maeda, Toyoaki Murohara, Shinya Toyokuni. Matrigel-based organoid culture of malignant mesothelioma reproduces cisplatin sensitivity through CTR1. BMC cancer. 2023. 23. 1. 487-487
  • Shingo Narita, Kazumasa Unno, Katsuhiro Kato, Yusuke Okuno, Yoshitaka Sato, Yusuke Tsumura, Yusuke Fujikawa, Yuuki Shimizu, Ryo Hayashida, Kazuhisa Kondo, et al. Direct reprogramming of adult adipose-derived regenerative cells toward cardiomyocytes using six transcriptional factors. iScience. 2022. 104651-104651
more...
MISC (75):
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page